Experience of drug treatment of multiple drug resistant acinetobacter bauman in severe pneumonia
10.3969/j.issn.1005-1678.2017.05.028
- VernacularTitle:多重耐药鲍曼不动杆菌重症肺炎的药物治疗体会
- Author:
Hui ZHANG
;
Xubo JIN
- Keywords:
multi drug resistanc;
acinetobacter bauman;
severe pneumonia
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(5):87-89
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the effect of different drugs on the treatment of severe pneumonia caused by multi drug resistant Acinetobacter Bauman, and to provide reference for clinical application in the future.MethodsA retrospective analysis was conducted on 250 cases of severe pneumonia patients with multiple drug resistant Acinetobacter Bauman admitted to intensive care unit in Yuyao Second People's Hospital from June 2011 to June 2016.The 250 cases were divided into the observation group and the control group, 125 cases in each group.The observation group were given imipenem (imipenem/cilastatin sodium), mepem (meropenem), sulperazone (Chuba Staw Na, cefoperazone) and levofloxacin, while the control group were given polymyxin E.The clinical efficacy, adverse reaction rate, C-reactive protein(CRP) and white blood cell count(WBC) were compared between the two groups.ResultsAfter treatment, the total effective rate in the observation group was 87.20% and 61.60% in the control group, the difference between the two groups was statistically significant, P<0.05.The adverse reaction rate in the observation group was 10.40% and 8.80% in the control group.There was no significant difference between the two groups about adverse reaction rarte.Inflammatory markers, CRP and WBC in the observation group were significantly lower than those in the control group, P<0.05.ConclusionImipenem, mepem, sulperazone and levofloxacin in treatment of severe pneumonia with multi drug resistant Acinetobacter Bauman, the clinical curative effect is good, less adverse reaction, is a drug treatment program that is worth promoting in clinical practice.
